KIR2DL3 and rheumatoid arthritis: No significant differences were observed for expression of the inhibitory KIR, CD158a and CD158b, in remission (0.09±0.02% and 0.93±0.32% respectively), active RA (0.05±0.01% and 0.66±0.14%) or controls (0.14±0.05% and 1.12±0.64%).